BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22118903)

  • 1. Effect of melatonin on α-synuclein self-assembly and cytotoxicity.
    Ono K; Mochizuki H; Ikeda T; Nihira T; Takasaki J; Teplow DB; Yamada M
    Neurobiol Aging; 2012 Sep; 33(9):2172-85. PubMed ID: 22118903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
    Ono K; Hirohata M; Yamada M
    J Neurosci Res; 2007 May; 85(7):1547-57. PubMed ID: 17387689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial Parkinson disease mutations influence α-synuclein assembly.
    Ono K; Ikeda T; Takasaki J; Yamada M
    Neurobiol Dis; 2011 Sep; 43(3):715-24. PubMed ID: 21684335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity.
    Takahashi R; Ono K; Takamura Y; Mizuguchi M; Ikeda T; Nishijo H; Yamada M
    J Neurochem; 2015 Sep; 134(5):943-55. PubMed ID: 26016728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.
    Ono K; Hirohata M; Yamada M
    Exp Neurol; 2007 Jun; 205(2):414-24. PubMed ID: 17425956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.
    Ono K; Yamada M
    J Neurochem; 2006 Apr; 97(1):105-15. PubMed ID: 16524383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases.
    Ono K; Yamada M
    Neurobiol Dis; 2007 Feb; 25(2):446-54. PubMed ID: 17169566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.
    Hirohata M; Ono K; Morinaga A; Yamada M
    Neuropharmacology; 2008 Mar; 54(3):620-7. PubMed ID: 18164319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells.
    Klongpanichapak S; Phansuwan-Pujito P; Ebadi M; Govitrapong P
    Neurosci Lett; 2008 May; 436(3):309-13. PubMed ID: 18406059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antiparkinsonian agents on β-amyloid and α-synuclein oligomer formation in vitro.
    Ono K; Takasaki J; Takahashi R; Ikeda T; Yamada M
    J Neurosci Res; 2013 Oct; 91(10):1371-81. PubMed ID: 23913715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
    Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical properties and cellular toxicity of covalent crosslinked oligomers of α-synuclein formed by photoinduced side-chain tyrosyl radicals.
    Borsarelli CD; Falomir-Lockhart LJ; Ostatná V; Fauerbach JA; Hsiao HH; Urlaub H; Paleček E; Jares-Erijman EA; Jovin TM
    Free Radic Biol Med; 2012 Aug; 53(4):1004-15. PubMed ID: 22771470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
    Ono K; Hirohata M; Yamada M
    Curr Pharm Des; 2008; 14(30):3247-66. PubMed ID: 19075704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-seeding effects of amyloid β-protein and α-synuclein.
    Ono K; Takahashi R; Ikeda T; Yamada M
    J Neurochem; 2012 Sep; 122(5):883-90. PubMed ID: 22734715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
    Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
    Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
    Ghee M; Melki R; Michot N; Mallet J
    FEBS J; 2005 Aug; 272(16):4023-33. PubMed ID: 16098186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds.
    Caruana M; Högen T; Levin J; Hillmer A; Giese A; Vassallo N
    FEBS Lett; 2011 Apr; 585(8):1113-20. PubMed ID: 21443877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells.
    Ko LW; Ko HH; Lin WL; Kulathingal JG; Yen SH
    J Neuropathol Exp Neurol; 2008 Nov; 67(11):1084-96. PubMed ID: 18957893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
    Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
    J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.